SEP
TXG icon

Signature Equity Partners’s 10x Genomics TXG Stock Holding History

Signature Equity Partners’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14K Buy
+365
New +$9.56K 0.01% 753

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Signature Equity Partners's TXG Position: Q2 2026 in Review

Signature Equity Partners opened a new position in 10x Genomics (TXG) in Q2 2026: 365 shares worth $14K. The stake represents 0.01% of the portfolio and ranks #753 among its holdings.

390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Signature Equity Partners held 365 shares of 10x Genomics worth $14K as of Q2 2026.
  • 10x Genomics was a new Signature Equity Partners position in Q2 2026.
  • 10x Genomics made up 0.01% of Signature Equity Partners's portfolio in Q2 2026, its #753 holding.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.